Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Amgen Says Denosumab Similar to Zometa in Study

By Pharmaceutical Processing | August 4, 2009

THOUSAND OAKS, Calif. (AP) — Amgen Inc. said Monday its drug denosumab met the goals of a late-stage study in treating patients with cancer that has spread to their bones, as it performed similarly to Novartis AG’s drug Zometa. The trial compared denosumab and Zometa in the treatment of bone metastases in 1,776 advanced cancer patients. Amgen said the two drugs had similar effects in delaying the length of time until a patient’s first bone injury and subsequent bone injuries. The company said denosumab was superior in both measurements, but the difference was not statistically significant. The bone injuries included fracture, radiation or surgery to bone, or spinal cord compression. Patients in the study received either a 120 mg subcutaneous injection of denosumab once every four weeks, or a 4 mg, 15-minute infusion of Zometa every four weeks. Amgen is seeking marketing approval for denosumab as a treatment for osteoporosis, and for the prevention of bone loss in patients being treated for breast or prostate cancer. The most recent study excluded patients with breast and prostate cancer, however. Amgen reported results from another late-stage trial in July. In that study, which involved patients with breast cancer that had spread to the bone, Amgen said cancer patients who were treated with denosumab were free of skeletal injury for longer than those who took Zometa. Results from a third study have not yet been reported. A Food and Drug Administration is scheduled to review Amgen’s marketing application for denosumab on Aug. 13, and is expected to make a decision by October.

Related Articles Read More >

FDA logo
FDA prevented 317 drug shortages in 2021
Pfizer-BioNTech vaccine vial
Pfizer, BioNTech moving forward on seeking COVID-19 vaccine EUA for youngest children
FDA logo
FDA curtails use of Janssen COVID-19 vaccine over blood clotting concerns
FDA logo
FDA sends warning letters to CBD and delta-8 THC product vendors

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards